Oncology

In the battle against lung cancer, a recent editorial examines the effectiveness of risk prediction models in determining screening eligibility.

Lung cancer remains one of the deadliest diseases worldwide, with changing risk factors influencing mortality rates.

A recent multicenter Phase II trial has demonstrated that combining chemoradiotherapy (CRT) with aggressive local consolidative therapy (LCT) can improve survival rates in patients with Stage IV non-small cell lung carcinoma (NSCLC) presenting with oligometastases.

A Phase II trial examining neoadjuvant therapy for difficult-to-resect cutaneous basal cell carcinoma (BCC) demonstrates promising outcomes.

Immune checkpoint inhibitors, widely used in cancer therapy, have revolutionized oncology but come with the risk of severe immune-related adverse events, including checkpoint myocarditis.

A groundbreaking study has revealed that white button mushrooms (WBM) may reduce immune suppression and enhance anti-cancer immune responses in patients with prostate cancer.

Colorectal cancer (CRC) screening guidelines may need to be more tailored, according to new research that identifies optimal stopping ages for screening based on sex, comorbidity status, and prior screening history.

The U.S. Food and Drug Administration (FDA) approved a novel combination therapy for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC).